Valuation: NetraMark Holdings Inc.

Market Cap 62.45M 44.88M 38.87M 36.76M 33.28M 4.3B 62.92M 439M 169M 2.18B 169M 165M 6.96B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 62.45M 44.88M 38.87M 36.76M 33.28M 4.3B 62.92M 439M 169M 2.18B 169M 165M 6.96B EV / Sales 2026 *
156x
EV / Sales 2027 * -
Free-Float
91.14%
Yield 2026 *
-
Yield 2027 * -
09-10 NetraMark Holdings Inc Publishes Peer-Reviewed Study Demonstrating NetraAI Uncovers Clinical Trial Signals Missed By Conventional AI And Foundation Models CI
09-01 Netramark Holdings Inc. Announces Appointment of Keith M. Fournier to Board of Directors CI
08-14 NetraMark Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026 CI
07-09 NetraMark Up 11% as It Signs a New Contract To Analyze Phase 2 Neurodegeneration Trial Data MT
07-09 NetraMark Holdings Inc. Signs Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner CI
06-29 NetraMark to Perform AI-Assisted Analysis of Clinical Trial Data For Biopharm Company MT
06-29 NetraMark Holdings Inc. Signs NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company CI
05-15 NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026 CI
05-08 NetraMark Holdings Inc. Announces Resignation of Lawrence Guy as Director, Effective May 7, 2026 CI
05-04 NetraMark Holdings Inc. Announces Executive Changes CI
04-22 NetraMark Holdings Inc. Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs CI
04-20 NetraMark Holdings Inc Announces NetraAI Platform For Clinical Trial Precision Analytics CI
04-09 Netramark Holdings Inc Announces Publication of Peer-Reviewed Article on Psychedelics and Quantum Brain Processes CI
1 day-7.88%
Current month-7.88%
1 month-21.17%
3 months-35.85%
6 months-50.64%
Current year-49.89%
1 month 0.4
Extreme 0.3985
0.43
Current year 0.4
Extreme 0.3985
0.89
1 year 0.4
Extreme 0.3985
1.15
3 years 0.11
Extreme 0.114
1.26
5 years 0.1
Extreme 0.1045
1.61
10 years 0.1
Extreme 0.1045
1.61
Manager TitleAgeSince
Chief Executive Officer - 17/02/2022
President - 04/07/2022
Director of Finance/CFO 57 18/07/2022
Director TitleAgeSince
Chairman 40 09/06/2025
Director/Board Member - -
Director/Board Member - 16/06/2022
Change 5-day change 1-year change 3-year change Capi.($)
-7.88%0.00% - - 44.88M
-1.64%+0.64%-3.54%+50.54% 3,753B
-0.43%+1.33%+0.79%+1,025.64% 416B
-1.83%-3.57%-22.06%+17.04% 76.85B
+0.10%+9.53%+66.08%+143.54% 82.61B
-3.60%-6.21%-12.29%-18.64% 73.1B
-5.55%-9.42%-46.10%+161.33% 66.56B
-1.54%+7.59%+9.17%-6.51% 48.8B
-4.93%-0.65%-14.29%+48.28% 41.68B
+4.43%+7.20%+131.78%+286.10% 35.61B
Average -1.72%+0.09%+12.17%+189.70% 510.51B
Weighted average by Cap. -1.41%-0.69%-1.87%+141.74%

Financials

2026 *2027 *
Net sales 401K 288K 250K 236K 214K 27.63M 404K 2.82M 1.08M 14.01M 1.08M 1.06M 44.69M -
Net income - -
Net Debt - -
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!